Trial reportBMJ paediatrics open2026
Pharmacokinetics, dosing exposure and safety of oral ibuprofen in Chinese preterm neonates with patent ductus arteriosus: preliminary report.
Trial report in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe use of oral ibuprofen to treat haemodynamically significant patent ductus arteriosus (hsPDA) in premature neonates is common. However, among Chinese preterm neonates, the available pharmacokinetic (PK) findings for its enantiomers remain merely descriptive. This study aimed to characterise the PKs, dosing exposure and safety of oral ibuprofen in Chinese preterm infants treated with hsPDA.
designA pilot trial.
settingThree perinatal centres across Southwest China. PATIENTS: Preterm infants (≤35 weeks' gestational age, ≥48 hours postnatal age) with suspected hsPDA (August 2022-May 2023).
interventionOral ibuprofen (10, 5 and 5 mg/kg at 24-hour intervals) was used and sparse sampling was performed.
main outcome measuresPlasma concentrations were analysed via ultrahigh-performance liquid chromatography-tandem mass spectrometry. The PK parameters were calculated via ADAPT 5 software. Adverse events and treatment efficacy were assessed.
results14 neonates provided 42 plasma samples. The R-ibuprofen (R-IBU) concentrations were lower than the S-ibuprofen (S-IBU) concentrations. The clearance values for rac-ibuprofen (rac-IBU), R-IBU and S-IBU were 24.22±37.04, 206.1±143.1 and 12.67±26.53 mL/kg/hour, respectively. The area under the curve (AUC
conclusionsThe recommended dosage regimen for Chinese preterm neonates with hsPDA may be insufficient to achieve targeted therapeutic exposure. Importantly, our study indicated that even at a relatively high dose, drug exposure might remain within the therapeutic window. Moreover, we observed a higher conversion ratio of R-IBU to S-IBU in these neonates than in adults. The use of ibuprofen may be associated with an elevated risk of jaundice in preterm infants. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry (ChiCTR2300067714).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.